Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally... Show more
The Moving Average Convergence Divergence (MACD) for EXAS turned positive on November 19, 2025. Looking at past instances where EXAS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where EXAS advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 197 cases where EXAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where EXAS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EXAS broke above its upper Bollinger Band on November 19, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.527) is normal, around the industry mean (11.922). P/E Ratio (0.000) is within average values for comparable stocks, (130.980). EXAS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.862). EXAS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (5.244) is also within normal values, averaging (9.717).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
a developer of proprietary technologies for the detection of cancer
Industry MedicalSpecialties
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| POWR | 25.37 | 0.04 | +0.14% |
| iShares U.S. Power Infrastructure ETF | |||
| JPIB | 48.80 | 0.01 | +0.02% |
| JPMorgan International Bond Opps ETF | |||
| JPI | 20.68 | N/A | N/A |
| Nuveen Preferred Securities & Income Opportunities Fund | |||
| HYKE | 24.98 | N/A | N/A |
| Vest 2 Year Interest Rate Hedge ETF | |||
| AVEE | 62.49 | -0.29 | -0.45% |
| Avantis Emerging Markets Sm Cp Eq ETF | |||
A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.
| Ticker / NAME | Correlation To EXAS | 1D Price Change % | ||
|---|---|---|---|---|
| EXAS | 100% | +23.68% | ||
| QGEN - EXAS | 55% Loosely correlated | +0.18% | ||
| RGEN - EXAS | 55% Loosely correlated | +1.31% | ||
| A - EXAS | 39% Loosely correlated | +0.39% | ||
| RVTY - EXAS | 39% Loosely correlated | -0.87% | ||
| MTD - EXAS | 38% Loosely correlated | +0.57% | ||
More | ||||